2025-02-02 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**0. Summary of Key Figures:**

* **Cumulative Return (JNJ):** 29.86%
* **Cumulative Return (VOO):** 119.91%
* **Return Difference (JNJ vs VOO):** -90.05% (JNJ underperformed VOO significantly)
* **Recent Closing Price:** $152.15
* **5-Day Moving Average:** $151.89
* **20-Day Moving Average:** $146.89
* **60-Day Moving Average:** $149.19
* **RSI:** 71.21 (Approaching overbought territory)
* **PPO:** 0.66 (Positive, indicating bullish momentum)
* **Relative Strength (20-day):** +5.8% (Short-term upward trend)
* **Expected Return (vs. S&P 500, long-term):** -338.8% (Significant underperformance projected)


**1. Performance Comparison & Company Overview:**

Johnson & Johnson is a multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.  Over the observed period, JNJ significantly underperformed the S&P 500 (VOO), with a cumulative return of 29.86% compared to VOO's 119.91%.  The -90.05% difference places JNJ's performance in the 7.7th percentile of its historical range relative to VOO, indicating consistently weaker performance.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 34.0% | 0.2% | 6.0% | -0.1 | 277.3 |
| 2016-2018  | 12.0% | 10.8% | -7.0% | 0.0 | 263.1 |
| 2017-2019  | 21.0% | 10.8% | -9.0% | 0.7 | 305.7 |
| 2018-2020  | 12.0% | 10.8% | -16.0% | 0.4 | 338.8 |
| 2019-2021  | 28.0% | 7.9% | -43.0% | 0.4 | 377.6 |
| 2020-2022  | 17.0% | 7.9% | 9.0% | 0.4 | 400.1 |
| 2021-2023  | -11.0% | 6.9% | -34.0% | 0.4 | 365.8 |
| 2022-2024  | -25.0% | 8.0% | -58.0% | 0.3 | 348.2 |
| 2023-2025  | -9.0% | 8.0% | -70.0% | 0.2 | 366.3 |

The table shows inconsistent performance over time, with periods of strong CAGR followed by periods of significant underperformance.  The negative Alpha values suggest the stock frequently underperformed its benchmark.


**2. Recent Price Movement:**

The recent closing price is $152.15, slightly below the previous close ($152.87), indicating a minor decline. The price is above the 5-day and 20-day moving averages, suggesting short-term upward momentum, but below the 60-day moving average, hinting at a longer-term downtrend.


**3. Technical Indicators and Expected Return:**

The RSI of 71.21 suggests the stock is approaching overbought territory, indicating potential for a near-term correction.  The positive PPO value (0.66) confirms bullish momentum.  The 20-day relative strength increase of 5.8% supports the short-term upward trend.  However, the projected long-term expected return of -338.8% relative to the S&P 500 raises serious concerns about future performance.  The recent price drop of -$0.47 does not signal a dramatic change in trend.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2024-10-23 | 1.12 | $22.47B     |
| 2024-07-25 | 1.95 | $22.45B     |
| 2024-05-01 | 1.35 | $21.38B     |
| 2024-02-16 | 1.68 | $21.39B     |
| 2023-10-27 | 10.32 | $21.35B     |

EPS shows significant volatility, with a large spike in Q4 2023.  Revenue remains relatively stable.  Further investigation is needed to understand the cause of the EPS fluctuation.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |
| 2023-12-31 | $21.39B   | 68.23%        |
| 2023-09-30 | $21.35B   | 69.06%        |

Revenue is relatively consistent, with high and stable profit margins.

**Capital and Profitability:**

| Quarter | Equity     | ROE          |
|---------|------------|--------------|
| 2024-09-30 | $70.16B   | 3.84%        |
| 2024-06-30 | $71.54B   | 6.55%        |
| 2024-03-31 | $70.02B   | 4.65%        |
| 2023-12-31 | $68.77B   | 5.89%        |
| 2023-09-30 | $71.23B   | 36.54%       |

Equity fluctuates, and ROE shows significant variability, particularly the exceptionally high ROE in Q3 2023 requires further investigation.


**6. Overall Analysis:**

JNJ shows a concerning pattern of underperformance against the S&P 500, despite relatively stable revenue and high profit margins.  The significant volatility in EPS and ROE warrants further investigation. While short-term indicators suggest some upward momentum, the long-term outlook is considerably negative based on the projected underperformance against the benchmark.  The substantial discrepancies in the data (especially the extreme Q3 2023 ROE and the projected -338.8% long-term return) require a thorough review of the data sources and assumptions to ensure accuracy.  Investors should proceed with caution and conduct further due diligence before making investment decisions.
